Skip to main content

Table 3 Between-group comparisons

From: Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial

Outcome Group N T1 (15 Min.) T2 (90 Min.) T3 (1 Day) T4 (2 Day)
8OHdG (ng/mL) MSM 11 10.87 (9.90–11.83) 10.72 (9.55–11.89) 9.12 (8.09–10.15) 9.13 (8.13–10.13)
Placebo 11 10.32 (9.36–11.29) 9.79 (8.61–10.96) 8.08 (7.05–9.11) 7.86 (6.86–8.86)
ΔGroup 0.54 (−0.84–1.92) 0.94 (−0.74–2.61) 1.04 (−0.43–2.51) 1.27 (−0.17–2.71)
MDA (μM) MSM 11 26.6 (21.7–31.4) 18.8 (14.9–22.6) 15.7 (13.3–18.1) 15.9 (13.0–18.8)
Placebo 11 22.9 (18.1–27.7) 17.9 (14.0–21.7) 16.7 (14.3–19.2) 18.7 (15.8–21.6)
ΔGroup 3.7 (−3.2–10.5) 0.9 (−4.6–6.4) −1.1 (−4.5–2.4) −2.8 (−6.9–1.4)
logCK (U/L) MSM 11 2.26 (2.08–2.43) 2.33 (2.15–2.52) 2.67 (2.38–2.95) 2.40 (2.14–2.66)
Placebo 11 2.24 (2.07–2.41) 2.30 (2.12–2.48) 2.49 (2.21–2.78) 2.29 (2.03–2.55)
ΔGroup 0.02 (−0.23–0.26) 0.03 (−0.23–0.29) 0.18 (−0.24–0.58) 0.11 (−0.26–0.48)
LDH (U/L) MSM 11 224.3 (199.2–249.3) 228.3 (199.3–257.2) 191.0 (172.2–209.7) 183.1 (163.4–202.7)
Placebo 11 236.5 (211.5–261.5) 236.6 (207.6–265.5) 185.8 (167.0–204.5) 177.1 (157.5–196.7)
ΔGroup −12.2 (−47.8–23.4) −8.3 (−49.5–32.9) 5.2 (−21.5–31.9) 6.0 (−22.0–33.9)
Muscle Pain (mm) MSM 11 28.7 (11.6–45.9) 28.3 (9.9–46.8) 31.2 (14.3–48.2) 21.8 (7.6–35.9)
Placebo 10 48.5 (32.2–64.9) 38.9 (21.2–56.5) 41.2 (25.0–57.3) 21.1 (7.6–34.6)
ΔGroup −19.8 a (−43.7–4.1) −10.6 a (−36.3–15.2) −10.0 a (−33.5–13.7) −0.7 (−20.4–19.1)
Joint Pain (mm) MSM 11 29.1 (14.7–43.5) 26.6 (9.6–43.6) 18.6 (2.9–34.2) 14.9 (−2.8–32.5)
Placebo 10 38.0 (24.2–51.7) 35.7 (19.5–51.9) 29.3 (14.4–44.2) 17.9 (1.1–34.7)
ΔGroup −8.9 (−29.1–11.3) −9.1 (−33.0–14.7) −10.7 a (−32.7–11.2) −3.0 (−27.8–21.7)
  1. Results adjusted for mean-centered baseline. Group results reported as Mean (95% confidence interval). ΔGroup indicates between group differences at each timepoint (MSM – Placebo), results reported with 95% confidence interval
  2. aClinically significant (ΔGroup ≥ 10) betweeen-group pain outcomes